HAYWARD, Calif., Oct. 31 /PRNewswire/ -- Metabolex, Inc. today announced the appointment of Paul Quinlan to the position of General Counsel. He joins Metabolex from Maxygen, Inc., where he served as Chief Corporate Securities Counsel.
“Paul brings to Metabolex more than a decade of legal, regulatory and business experience, as well as substantial biotech experience, which includes strategic collaborations and licensing,” said Harold Van Wart, Ph.D., president and chief executive officer of Metabolex. “Paul’s legal experience and training will be a valuable addition to Metabolex as we seek to partner our lead product candidate, metaglidasen, and move it into late-stage development, as well as advance our vision of developing first-in-class, breakthrough therapeutics to treat diabetes and metabolic diseases.”
In his position as Chief Corporate Securities Counsel and Compliance Officer at Maxygen, a $400 million public biotechnology company in Redwood City, Calif., Mr. Quinlan was responsible for all securities law, compliance and general corporate legal work, including SEC reporting and compliance, securities registration, corporate governance and mergers and acquisitions. He also negotiated and drafted key strategic collaboration and licensing agreements. While at Maxygen, he helped negotiate two major licensing deals and a joint venture.
From 1998 to 2000, Mr. Quinlan was an Associate at Cooley Godward LLP, in Palo Alto, Calif. While there, he served as primary outside counsel for several public and private companies and led several successful IPOs. From 1994 to 1998, he was an Associate at Cravath Swaine & Moore, in New York, where he provided transaction assistance to Fortune 50 companies, including mergers and acquisitions transactions and public and private offerings of debt and equity.
Mr. Quinlan received his Master of Laws from Columbia University School of Law in New York and his Bachelor of Laws from Queen’s University in Kingston, Ontario. He earned a Master of Science and a Bachelor of Science degree from the University of Toronto.
About Metabolex
Metabolex is a privately held biotechnology company dedicated to the discovery and development of novel therapeutics to transform the treatment of diabetes and related metabolic disorders. Metabolex has drawn on its deep understanding of diabetes to create the largest database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company’s clinical program is focused on developing next- generation insulin sensitizers that lower blood glucose without the serious safety and tolerability issues associated with currently marketed products.
For additional information about Metabolex and its development pipeline, visit www.metabolex.com.
Metabolex, Inc.
CONTACT: Mark Bagnall of Metabolex, Inc., +1-510-293-8800, ormbagnall@metabolex.com; or Daryl Messinger of WeissComm Partners,+1-415-999-2361, or daryl@weisscommpartners.com, for Metabolex, Inc.
Web site: http://www.metabolex.com/
